title: Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD.
abstract: OBJECTIVE
  We describe the neuroimaging characteristics of prodromal AD (PrdAD) patients diagnosed using the new research criteria in a clinical setting. In order to further characterize these patients, we also study the relationship between neuropsychology, CSF biomarkers and magnetic resonance imaging (MRI) findings.
  
  
  METHODS
  76 participants--24 controls (CTR), 20 amnesic patients, and 32 Alzheimer's disease (AD) patients--were included in the study. PrdAD was defined on the basis of an objective episodic memory deficit and an AD CSF profile. Structural MRI was performed in all participants.
  
  
  RESULTS
  After FWE correction, voxel-based morphometry (VBM) analysis of PrdAD patients versus CTR showed significant clusters of decreased gray matter (GM) volume in the left hemisphere regions including the parahippocampal gyrus, uncus, precuneus, and middle frontal gyrus. We did not find differences in brain atrophy between PrdAD and mild AD patients. Some significant associations were found between CSF levels and episodic and semantic fluency tests in the PrdAD group. Correlations in the PrdAD group revealed that patients with higher scores on delayed free recall had significantly greater GM volume in the left superior temporal gyrus (t = 6.64, p < 0.0001).
  
  
  CONCLUSIONS
  PrdAD patients presented mainly medial temporal GM atrophy, which was related with significant episodic memory impairment. The cognitive deficit observed in PrdAD patients was also associated with CSF biomarker levels.
authors.affiliation: Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain.
authors.forename: Lorena
authors.initials: L
authors.lastname: Rami
authors.forename: Cristina
authors.initials: C
authors.lastname: Solé-Padullés
authors.forename: Juan
authors.initials: J
authors.lastname: Fortea
authors.forename: Beatriz
authors.initials: B
authors.lastname: Bosch
authors.forename: Albert
authors.initials: A
authors.lastname: Lladó
authors.forename: Anna
authors.initials: A
authors.lastname: Antonell
authors.forename: Jaume
authors.initials: J
authors.lastname: Olives
authors.forename: Magda
authors.initials: M
authors.lastname: Castellví
authors.forename: David
authors.initials: D
authors.lastname: Bartres-Faz
authors.forename: Raquel
authors.initials: R
authors.lastname: Sánchez-Valle
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Molinuevo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000523:psychology; D000647:Amnesia / Q000134:cerebrospinal fluid / Q000473:pathology* / Q000523:psychology; D001284:Atrophy / Q000473:pathology; D015415:Biomarkers / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009483:Neuropsychological Tests; D016875:tau Proteins / Q000134:cerebrospinal fluid
chemical_list: D015415:Biomarkers; D016875:tau Proteins